Date: 2016-03-01
Type of information: Opening of new premises
Compound: manufacturing and services facility in Louisville
Company: Eurofins Scientific (France)
Therapeutic area: Technology - Services
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On March 1, 2016, Eurofins Scientific, a global leader in bio-analytical testing and genomic services, announced the opening of its new state-of-the-art manufacturing and services facility in Louisville, KY, in the US. The large, 65,800 ft2(6,113 m2) facility functions as the Group’s central genomics laboratory in North America, focusing on the custom production of DNA and RNA oligonucleotides synthetic gene synthesis, and genomics services including DNA sequencing, synthetic biology, and next generation sequencing (NGS).
As a leader in analytical laboratory technology, Eurofins continues to expand its global infrastructure of advanced laboratories. Since 2005, Eurofins has invested over $800,000,000 dollars to add or modernize over 350,000m2 of laboratory surface to its network, and plans to add another 120,000m2 by the end of 2017. The Louisville, KY facility will be one of the newest and most advanced genomics facilities in the world. As a multi-functional hub, the site will also house other activities such as food and microbiology testing, which should foster diversity and synergy between scientific applications of molecular testing.
The company will introduce new, proprietary synthesis technology in the new facility, which will lead to increased quality and reliability in its oligonucleotides production capabilities. Quality standards implemented during construction are already among the highest in the industry and supported by several internationally recognized certifications such as ISO 9001:2008, ISO 13485: 2003 and an FDA certification for GMP production.
Located in the central hub for a major courier service operator, the new site offers unparalleled accessibility to the major cities in the US, and will allow Eurofins Genomics to become the fastest provider of genomics services in the marketplace.
Financial terms:
Latest news:
